Premium
Thrombolytic and anticoagulation treatment in a rat embolic stroke model
Author(s) -
Rasmussen R. S.,
Overgaard K.,
Meden P.,
Boysen G.
Publication year - 2003
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2003.00096.x
Subject(s) - thrombolysis , medicine , tissue plasminogen activator , stroke (engine) , embolic stroke , recombinant tissue plasminogen activator , t plasminogen activator , anesthesia , gastroenterology , surgery , ischemic stroke , myocardial infarction , ischemia , mechanical engineering , engineering , modified rankin scale
Objectives – The effects of pentasaccharide (PENTA), given alone or combined with thrombolysis using recombinant tissue plasminogen activator (rt‐PA), on infarct size and clinical outcome were evaluated in a rat embolic stroke model. Materials and methods – Ninety‐two rats were embolized unilaterally and assigned to: (i) controls, (ii) rt‐PA 6 mg/kg, (iii) PENTA 0.5 mg/kg, (iv) PENTA 0.5 mg/kg and rt‐PA 6 mg/kg. After 2 days animals were killed, the brains removed and evaluated microscopically. Results – The median infarct size measured in percentage of the affected hemisphere was 25% in the control group, 4% ( P < 0.01, Mann–Whitney) in group 2, 19% (n.s.) in group 3, and 10% ( P < 0.05) in group 4. rt‐PA, and rt‐PA combined with PENTA also promoted functional recovery. Conclusion – The present study found no effect of 0.5 mg/kg PENTA treatment. Compared with rt‐PA treatment alone, 0.5 mg/kg PENTA alone or combined with rt‐PA did not significantly increase mortality or tendency for hemorrhage.